|
CN104740624B
(zh)
|
2007-09-18 |
2018-04-24 |
武田疫苗股份有限公司 |
赋予针对诺如病毒的保护性免疫应答的疫苗
|
|
PH12014500093A1
(en)
|
2011-07-11 |
2014-03-17 |
Takeda Vaccines Inc |
Parenteral norovirus vaccine formulations
|
|
KR101520534B1
(ko)
|
2012-05-07 |
2015-05-21 |
고려대학교 산학협력단 |
말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
|
|
JP2020517259A
(ja)
*
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
WO2019094725A2
(en)
|
2017-11-09 |
2019-05-16 |
Sangamo Therapeutics, Inc. |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
|
CN115710576A
(zh)
|
2018-02-01 |
2023-02-24 |
Nkmax有限公司 |
产生天然杀伤细胞的方法和用于治疗癌症的组合物
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
AU2019271366B2
(en)
*
|
2018-05-16 |
2026-02-26 |
Research Institute At Nationwide Children's Hospital |
Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
EP3947647A4
(en)
*
|
2019-03-29 |
2023-01-04 |
Board of Regents, The University of Texas System |
METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF
|
|
CN114174325A
(zh)
*
|
2019-06-04 |
2022-03-11 |
恩卡尔塔公司 |
用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
US12195723B2
(en)
*
|
2019-11-08 |
2025-01-14 |
The Broad Institute, Inc. |
Engineered antigen presenting cells and uses thereof
|
|
CN110760007B
(zh)
*
|
2019-11-21 |
2022-08-26 |
博生吉医药科技(苏州)有限公司 |
Cd7-car-t细胞及其制备和应用
|
|
CA3163258A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of nk cells
|
|
EP4065138A4
(en)
*
|
2019-11-27 |
2024-02-28 |
Board of Regents, The University of Texas System |
LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
BR112022013445A2
(pt)
*
|
2020-01-08 |
2022-09-13 |
Univ Texas |
Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos
|
|
JP7773789B2
(ja)
|
2020-03-28 |
2025-11-20 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
癌の治療のための細胞免疫療法
|
|
WO2021202581A1
(en)
*
|
2020-03-30 |
2021-10-07 |
WUGEN, Inc. |
Engineered immune cells for adoptive cell therapy
|
|
CN113913458A
(zh)
*
|
2020-07-09 |
2022-01-11 |
杭州优凯瑞医药科技有限公司 |
非病毒方法制备稳定高表达嵌合受体的nk细胞
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
EP4255453A4
(en)
*
|
2020-12-03 |
2025-03-26 |
Nkarta, Inc. |
Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
US20240115606A1
(en)
|
2020-12-15 |
2024-04-11 |
Universiteit Antwerpen |
Cell-Based Therapeutics Targeting CD70
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
WO2022173737A1
(en)
|
2021-02-09 |
2022-08-18 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for freezing and thawing mammalian cells
|
|
CN113005151A
(zh)
*
|
2021-03-12 |
2021-06-22 |
广东药科大学 |
一种kdr-car-nk细胞的制备方法及其应用
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
AU2022266583A1
(en)
|
2021-04-26 |
2023-10-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
|
WO2022242700A1
(en)
*
|
2021-05-20 |
2022-11-24 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Genetically modified nk cells and uses thereof
|
|
JP2024522756A
(ja)
*
|
2021-06-18 |
2024-06-21 |
オーエヌケイ セラピューティクス リミテッド |
ダブルノックアウトナチュラルキラー細胞
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
CN113599395B
(zh)
*
|
2021-09-22 |
2022-08-12 |
郑州源创吉因实业有限公司 |
含有nk细胞的治疗癌症的药物组合物
|
|
WO2023056330A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Antibody loaded immune cells and methods for use in cancer treatment
|
|
WO2023062113A1
(en)
*
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
EP4419541A4
(en)
*
|
2021-10-21 |
2025-12-17 |
Univ Texas |
METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL
|
|
AU2022381757A1
(en)
*
|
2021-11-04 |
2024-05-09 |
Saliogen Therapeutics, Inc. |
Immune cells with chimeric antigen receptors or chimeric autoantibody receptors
|
|
UY40023A
(es)
|
2021-11-18 |
2023-05-31 |
Janssen Biotech Inc |
Métodos de cultivo celular sin alimentadora para la expansión de preparaciones de células destructoras naturales
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN114774364B
(zh)
*
|
2022-04-26 |
2024-04-26 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN120152735A
(zh)
*
|
2022-10-25 |
2025-06-13 |
武田药品工业株式会社 |
Adgre2嵌合受体nk细胞组合物和使用方法
|
|
CN120091827A
(zh)
*
|
2022-11-10 |
2025-06-03 |
昂克医疗有限公司 |
使用免疫调节药物的联合疗法
|
|
CN115947869B
(zh)
*
|
2022-11-28 |
2023-12-12 |
广州佰芮慷生物科技有限公司 |
一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途
|
|
CN115948344A
(zh)
*
|
2023-02-10 |
2023-04-11 |
上海交通大学 |
嵌合抗原受体nk细胞、制备方法及其用途
|
|
CN116731972A
(zh)
*
|
2023-02-10 |
2023-09-12 |
上海交通大学 |
嵌合抗原受体t细胞、制备方法及其用途
|
|
JP2026511162A
(ja)
*
|
2023-03-24 |
2026-04-10 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
強化された抗腫瘍記憶応答を備える操作されたナチュラルキラー細胞
|
|
WO2024211554A1
(en)
*
|
2023-04-07 |
2024-10-10 |
Nkarta, Inc. |
Methods for treatment of autoimmune diseases
|
|
CN116769722B
(zh)
*
|
2023-07-04 |
2024-07-16 |
杭州荣谷生物科技有限公司 |
功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用
|
|
CN121969385A
(zh)
|
2023-09-11 |
2026-05-01 |
丹娜-法伯癌症研究院 |
含有il-2变体以增强car t细胞的功能性的car-衔接子
|
|
EP4788796A1
(en)
*
|
2023-10-05 |
2026-08-12 |
ONK Therapeutics Limited |
Optimised il-15 constructs
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|